Loading...
01/10 22:43
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: record high revenue and strong ACV growth are positive, but operational losses and increased expenses due to currency fluctuations are concerning. Management's optimistic guidance is tempered by geopolitical risks and trade uncertainties. The Q&A reveals steady licensing activity and potential growth in FlexGen, but no acceleration in decision timelines. The lack of guidance on book-to-bill ratio is a red flag. Given these factors, a neutral stock price movement is likely, as positives are balanced by risks and uncertainties.
Total Revenue $16.5 million, up 28% year-over-year, benefiting from approximately $0.5 million onetime revenue.
Annual Contract Value (ACV) plus Royalties $66.8 million, up 15% year-over-year, a record high for the company.
Remaining Performance Obligations (RPO) $88.9 million, representing a 19% year-over-year increase, a new high for Arteris.
Non-GAAP Gross Profit $15.3 million, representing a gross margin of 92%.
GAAP Gross Profit $15.0 million, representing a gross margin of 91%.
Non-GAAP Operating Expense $18.4 million, up 8% year-over-year, impacted by the timing of certain nonlinear expenses and a weaker U.S. dollar.
GAAP Operating Expense $22.7 million, representing a 10% year-over-year increase.
Non-GAAP Operating Loss $3.2 million, a $2.1 million or 40% improvement compared to the loss of $5.3 million in the prior year period.
GAAP Operating Loss $7.7 million, compared to a loss of $9.1 million in the prior year period.
Non-GAAP Net Loss $3.6 million or diluted net loss per share of $0.09.
GAAP Net Loss $8.1 million or diluted net loss per share of $0.20.
Cash, Cash Equivalents, and Investments $55.1 million, with no financial debt.
Free Cash Flow Positive $2.7 million for the quarter, benefiting from early customer payments.
New Product Launches: Arteris announced the release of FlexGen, an AI-driven smart NoC IP technology, which aims to enhance semiconductor designs by improving engineering productivity and performance. Over 20 customer SoC projects are currently evaluating FlexGen.
Product Updates: The latest generation of Magillem register management automation software was released, aimed at improving SoC and chiplet development by providing a single source of data for various teams.
Market Expansion: Arteris has expanded its customer base to include 10 automotive OEMs, with significant design wins from top global technology companies and a major Japanese automotive OEM.
Ecosystem Collaboration: Arteris joined the Intel Foundry Accelerator Program and became a founding member of the Chiplet Alliance to enhance collaboration and interoperability in silicon designs.
Operational Efficiency: The company reported a positive free cash flow of $2.7 million for Q1 2025, driven by early customer payments.
Cost Management: Non-GAAP operating expenses increased by 8% year-over-year, but G&A spending has remained flat for three years, indicating effective cost control.
Strategic Shifts: Arteris is seeing a shift from internal system IP solutions to commercial vendors, as customers seek resource efficiency and faster solution delivery.
Geographic Expansion: The opening of a new engineering and customer support center in Kraków, Poland, aims to enhance product development and customer support.
Economic Uncertainty: The company is monitoring global economic uncertainty, which could lead to variability in financial outcomes for the year.
Royalties and Demand: Potential short-term headwinds to royalties due to waning customer global confidence and automotive tariffs.
Operational Expenses: Increased operational expenses due to the weakness of the U.S. dollar, which could add approximately $1 million to annual expenses.
Trade Challenges: Current trade challenges may reduce end demand for customers' products, particularly in automotive and consumer sectors.
Geopolitical Uncertainty: Ongoing trade disputes and geopolitical factors may impact consumer and industrial confidence, affecting the business environment.
Annual Contract Value plus Royalties: Achieved a record of $66.8 million in Q1 2025, driven by demand for semiconductor system IP products.
Design Wins: Secured multiple key design wins, including contracts with top global technology companies and automotive OEMs for next-generation EV vehicles and autonomous driving SoCs.
FlexGen Technology: Launched FlexGen, an AI-driven smart NoC IP technology, with over 20 customer SoC projects evaluating it, expected to generate revenue in the second half of 2025.
Ecosystem Collaboration: Joined Intel Foundry Accelerator Program and Chiplet Alliance to enhance collaboration and interoperability in semiconductor designs.
New Engineering Center: Opened a new engineering and customer support center in Kraków, Poland to expand global footprint and access to engineering talent.
Q2 2025 Revenue Guidance: Expected revenue of $16.1 million to $16.5 million, with ACV plus royalties of $66 million to $70 million.
Full Year 2025 Revenue Guidance: Projected revenue of $65 million to $71 million, with ACV plus royalties expected to exit at $71 million to $79 million.
Non-GAAP Operating Loss Guidance: For Q2 2025, expected non-GAAP operating loss of $4 million to $3 million; for full year 2025, loss projected between $14 million to $7 million.
Free Cash Flow Guidance: For Q2 2025, expected free cash flow of negative $5 million to 0; for full year 2025, guidance of 0 to positive $8 million.
Free Cash Flow Q1 2025: Positive $2.7 million
Free Cash Flow Guidance for Q2 2025: Negative $5 million to $0
Free Cash Flow Guidance for FY 2025: $0 to Positive $8 million
The earnings call summary shows strong financial performance with significant revenue growth, high gross margins, and positive free cash flow. The Q&A highlights opportunities with major companies like AMD and Altera, and the focus on AI and data centers is promising. The management's avoidance of booking details is a minor concern, but overall, the optimistic guidance, strong partnerships, and strategic investments suggest a positive outlook for the stock price.
The earnings call reveals strong financial performance with a 13% increase in revenue and a 15% rise in ACV plus royalties, reflecting growing demand. Record high revenue and strategic wins with major clients like AMD are positive indicators. While there are some concerns about expenses, the optimistic guidance for revenue and cash flow, alongside strategic partnerships and product developments, suggests a positive outlook. However, the lack of clarity on certain metrics in the Q&A slightly tempers enthusiasm, but the overall sentiment remains positive, likely leading to a stock price increase of 2% to 8%.
The earnings call presents mixed signals: record high revenue and strong ACV growth are positive, but operational losses and increased expenses due to currency fluctuations are concerning. Management's optimistic guidance is tempered by geopolitical risks and trade uncertainties. The Q&A reveals steady licensing activity and potential growth in FlexGen, but no acceleration in decision timelines. The lack of guidance on book-to-bill ratio is a red flag. Given these factors, a neutral stock price movement is likely, as positives are balanced by risks and uncertainties.
The earnings call shows strong financial performance with record high revenues and significant annual contract value plus royalties. Despite operational losses, improvements were noted, and guidance remains optimistic. The Q&A section highlighted strong product adoption and positive ASP trends. However, management's lack of clarity on specific bookings figures slightly tempers enthusiasm. Overall, the positive financial metrics and guidance suggest a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
